Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by Gbathaton Mar 31, 2021 8:46am
325 Views
Post# 32912616

Why are people suddenly investing in ProMIS?

Why are people suddenly investing in ProMIS?ProMIS has always been a company with tremendous technical potential and a huge potential market, but recently there have finally been some great business developments.

A group of world renowned business magnates provided $7M in financing to ProMIS and stated that their due diligence indicates the technology has tremendous potential. This investment will be used to transition PMN310 into Phase 1 clinical trials for treatment of Alzheimer's disease, one of the biggest unmet needs in the world.


https://www.globenewswire.com/news-release/2021/03/22/2197066/0/en/ProMIS-Neurosciences-Completes-US-7M-CDN-8-75M-Financing-with-Distinguished-Group-of-Boston-Based-Investors.html

Sidenote: LeBron James might become an indirect investor in ProMIS as well, haha...
https://www.bostonglobe.com/2021/03/16/sports/fenway-sports-group-adds-lebron-james-partner-approves-deal-jump-start-plan-acquire-more-teams/

One of PMNs 50-50 JV partners who is developing a COVID serology assay that rapidly analyzes and classifies antibodies is now officially taking patient referral forms for testing. The test is described as 'awaiting accreditation,' likely indicating that accreditation is actively being sought. This assay is unique in its ability to distinguish antibodies that may correlate with immunity.
https://bcneuro.ca/wp-content/uploads/2021/03/Req-2.5-March-2021.pdf
<< Previous
Bullboard Posts
Next >>